

Nr. crt.	Cod protocol	Numar EudraCT	Medicament de investigatie clinica testat	Medicament de investigatie clinica comparator	Placebo	Aria terapeutică	Sponsor	International / national	Denumirea studiului (s-a pastrat denumirea originala - in limba engleza)	Faza	Nr. estimat de pacienti pentru Romania	Data autorizarii studiului clinic de catre ANMMD	Data opiniei CNBMDM	Data inceperii studiului	Inchidere studiu la nivel global/ Romania	Inchidere temporara
1	CF101-301RA	2016-003682-26	CF101	Methotrexate	Da	Afecțiuni ale sistemului musculo-scheletic	Can-Fite BioPharma, Ltd., Israel	multicentric	A Phase 3, Randomized, Double-Blind, Active- and Placebo controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis	III	144	2/4/2019		20.03.2019		
2	RAAINBOW	2016-003208-30	LH-8	Nu	Da	Afecțiuni ale pielii și țesutului conjunctiv	Legacy Healthcare (France) SAS, Franța	multicentric	Double-blind, vehicle-controlled, randomized, multi-centre study to evaluate the efficacy and safety of LH-8 cutaneous solution in children and adolescents with moderate to severe scalp alopecia areata	II/III	50	2/4/2019	10/26/2017			
3	CABL001A2301	2016-002461-66	ABL001	Bosulif® (bosutinib)	Nu	Afecțiuni oncologice	Novartis Pharma AG, Elveția	multicentric	A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	III	8	2/5/2019	12/21/2017			
4	BAY63-2521/15681	2014-003952-29	Adempas 0,5mg (Riociguat)	Nu	Nu	Afecțiuni cardiovasculare	Bayer AG, Germania	multicentric	Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (PAH)	III	4	2/27/2019				
5	CQAW039A2317	2017-001272-40	fevipirant (QAW039)	Nu	Nu	Afecțiuni ale tractului respirator	Novartis Pharma AG, Elveția	multicentric	A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma	III	18	2/19/2019				
6	CICL670F2203	2016-002529-12	Exjade® (deferasirox, ICL670)	Flebotomie	Nu	Afecțiuni și anomalii congenitale, ereditare și neonatale	Novartis Pharma AG, Elveția	multicentric	A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis	II	8	2/4/2019	1/23/2018	2/20/2019		
7	CA209-901	2016-003881-14	Nivolumab combinatie cu Ipilimumab	Standard of Care	Nu	Afecțiuni oncologice	Bristol-Myers Squibb International Corporation, Belgia	multicentric	A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer	III	20	2/19/2019		2/25/2019		
8	RPC01-3201	2017-004292-31	Ozanimod	Nu	Da	Afecțiuni ale sistemului digestiv	Celgene International II Sàrl, Elveția	multicentric	Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease	III	26	2/4/2019				
9	E7080-G000-604	2017-003668-11	Lenvatinib E7080	Brat cu tratament comparator	Da	Afecțiuni oncologice	Eisai Ltd., UK	unicentric	An open-label, multi-center, roll-over study to assess long term safety of lenvatinib monotherapy or lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored lenvatinib trials	II	3	2/19/2019	7/16/2018			
10	D9484C00001	2018-000175-33	Sodium zirconium cyclosilicate OS AZD7270	Nu	Da	Afecțiuni cardiovasculare	AstraZeneca AB, Suedia	multicentric	A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy with Sodium Zirconium Cyclosilicate in Heart Failure (PRIORITIZE HF)	II	50	2/5/2019				
11	EFC14828	2017-002954-35	Efpeglenatide	Nu	Da	Afecțiuni nutriționale și metabolice	sanofi-aventis recherche & développement, Franța	multicentric	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk	III	100	2/15/2019	12/10/2018			
12	204837	2017-004372-56	Daprodustat	Recombinant human erythropoietin	Da	Afecțiuni limfatice și ale sângelui	GlaxoSmithKline Research & Development Ltd., Marea Britanie	multicentric	A Phase 3 randomized, double-blind, active-controlled, parallel-group, multi-center study in hemodialysis participants with anemia of chronic kidney disease to evaluate the efficacy, safety and pharmacokinetics of three-times weekly dosing of daprodustat compared to recombinant human erythropoietin, following a switch from recombinant human erythropoietin or its analogs	III	8	2/4/2019				

13	GFT505-118-13/OP103817.GEN	2018-002481-39	//	Nu	Nu	//	//	//	//	I	12	2/13/2019				
14	Debio 1143-NSCLC-105	2018-000494-71	//	Nu	Nu	//	//	//	//	I	8	2/13/2019				
15	MS100070_0176	2018-003711-21	Avelumab	Nu	Nu	Afecțiuni oncologice	Merck KGaA, Germania	unicentric	An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies	III	1	2/27/2019				